This article is more than 5 years old. Information may no longer be current.

X-GEN Pharmaceuticals to market acetazolamide for glaucoma

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

BIG FLATS, N.Y. — X-GEN Pharmaceuticals will begin marketing acetazolamide for injection, the equivalent of Diamox (Duramed Pharmaceuticals), for ophthalmic indications, the company announced in a press release.

Specifically, the drug is indicated for treating chronic open-angle glaucoma and secondary glaucoma and for preoperative use in acute angle-closure glaucoma when surgery is postponed to lower IOP.

Acetazolamide is a sterile, preservative-free, lyophilized powder, and each vial contains acetazolamide sodium equivalent to 500 mg of acetazolamide, the release said.